I do know from preparing for the hearing, Mr. Mitchell, that the FTC has filed amicus briefs in cases, including the case involving Celgene and Revlimid, saying that Revlimid--Celgene's behavior is anticompetitive and arguing that the REMS' excuse is just that, a pretext.
Mitchell discusses FTC's stance on Celgene's anticompetitive behavior.
Share
More from Paul Mitchell
Justice for the victims of the Brothers to the Rescue shoot-down is a linchpin case for other Americans seeking justice for a wide range of crimes committed by Cuban outlaws.
They have evolved into being a regulatory agency, a gatekeeper, which makes it a tremendously distorted approach.
Inflammatory statements targeting anyone on the base of their ethnicity or origin are wrong.
I came to the hearing today in admittedly the naive hope that we'd actually talk about regulatory improvement and streamlining and not simply the political environment.
Other voices in this conversation
